Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression. In the last three decades, histone deacetylases (HDACs) are among the most studied epigenetic targets. In fact, aberrant HDAC expression is associated with numerous types of cancer and neurodegenerative disorders, making HDACs promising molecular targets for the design of new drugs. Many HDAC inhibitors (HDACi) are currently in clinical evaluation for various types of cancer, and some of them have reached the market after approval by the Food and Drug Administration (FDA). The present review summarizes the various HDAC classes and relative isoforms. Then we discuss different classes or isoform-selective HDACi with a strong emphasis on late-stage preclinical candidates and drugs in clinical studies. Last but not least, we shed light on the pharmacokinetic challenges and future directions in HDACi design.

Current HDAC inhibitors in clinical trials / DI BELLO, Elisabetta; Noce, Beatrice; Fioravanti, Rossella; Mai, Antonello. - In: CHIMIA. - ISSN 0009-4293. - 76:5(2022), pp. 448-6. [10.2533/chimia.2022.448]

Current HDAC inhibitors in clinical trials

Elisabetta Di Bello;Beatrice Noce;Rossella Fioravanti
;
Antonello Mai
2022

Abstract

Epigenetic modifications in eukaryotic biological pathways can lead to the up- or downregulation of regulatory proteins contributing to disease onset and progression. In the last three decades, histone deacetylases (HDACs) are among the most studied epigenetic targets. In fact, aberrant HDAC expression is associated with numerous types of cancer and neurodegenerative disorders, making HDACs promising molecular targets for the design of new drugs. Many HDAC inhibitors (HDACi) are currently in clinical evaluation for various types of cancer, and some of them have reached the market after approval by the Food and Drug Administration (FDA). The present review summarizes the various HDAC classes and relative isoforms. Then we discuss different classes or isoform-selective HDACi with a strong emphasis on late-stage preclinical candidates and drugs in clinical studies. Last but not least, we shed light on the pharmacokinetic challenges and future directions in HDACi design.
2022
cancer; clinical studies; epigenetics; histonede acetylases
01 Pubblicazione su rivista::01g Articolo di rassegna (Review)
Current HDAC inhibitors in clinical trials / DI BELLO, Elisabetta; Noce, Beatrice; Fioravanti, Rossella; Mai, Antonello. - In: CHIMIA. - ISSN 0009-4293. - 76:5(2022), pp. 448-6. [10.2533/chimia.2022.448]
File allegati a questo prodotto
File Dimensione Formato  
Di Bello_Current-HDAC_2022.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 343.5 kB
Formato Adobe PDF
343.5 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1644085
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
social impact